CNY:PA:PA-HSBC MSCI China UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 6.261

Change

+0.10 (+1.69)%

Market Cap

USD 0.59B

Volume

0.08M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.36 (-0.78%)

USD 64.41B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

-0.60 (-0.12%)

USD 12.63B
WRD:PA HSBC ETFs Public Limited Compa..

-0.10 (-0.31%)

USD 10.26B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-2.37 (-0.96%)

USD 8.94B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

-0.15 (-0.03%)

USD 7.87B
HHH:PA HSBC ETFs Public Limited Compa..

-0.08 (-0.15%)

USD 7.03B
WLD:PA Lyxor UCITS MSCI World D-EUR

-0.75 (-0.22%)

USD 6.87B
LCWD:PA Multi Units Luxembourg - Lyxor..

-0.05 (-0.28%)

USD 6.47B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

-0.32 (-0.09%)

USD 5.17B
S500:PA Amundi S&P 500 ESG UCITS ETF A..

-0.25 (-0.17%)

USD 4.78B

ETFs Containing CNY:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.69% 91% A- 88% B+
Dividend Return N/A 3% F 9% A-
Total Return N/A 3% F 1% F
Trailing 12 Months  
Capital Gain 12.81% 33% F 56% F
Dividend Return N/A 53% F 51% F
Total Return N/A 1% F 18% F
Trailing 5 Years  
Capital Gain -7.31% 17% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.31% 16% F 32% F
Average Annual (5 Year Horizon)  
Capital Gain -7.38% N/A N/A 19% F
Dividend Return N/A N/A N/A 23% F
Total Return N/A N/A N/A 23% F
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A 22% F
Risk Adjusted Return N/A N/A N/A 81% B-
Market Capitalization 0.59B 71% C- 72% C

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike